Last reviewed · How we verify
Minocycline hydrochloride capsules
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Bacterial infections susceptible to tetracyclines (acne, respiratory infections, urinary tract infections, rickettsial infections).
At a glance
| Generic name | Minocycline hydrochloride capsules |
|---|---|
| Also known as | DFD-29 |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Minocycline hydrochloride is a second-generation tetracycline antibiotic that penetrates bacterial cells and binds to the 30S ribosomal subunit, blocking aminoacyl-tRNA from entering the A site and preventing peptide bond formation. This inhibition of protein synthesis is bacteriostatic, stopping bacterial growth and allowing the immune system to clear the infection. Minocycline has broad-spectrum activity against gram-positive and gram-negative bacteria, as well as some atypical organisms.
Approved indications
- Bacterial infections susceptible to tetracyclines (acne, respiratory infections, urinary tract infections, rickettsial infections)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Photosensitivity
- Dizziness or vertigo
- Vaginal candidiasis
Key clinical trials
- Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke (PHASE2)
- Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (NA)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Evaluating the Role of Neuroinflammation in Low Back Pain (PHASE2)
- Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage (PHASE3)
- Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minocycline hydrochloride capsules CI brief — competitive landscape report
- Minocycline hydrochloride capsules updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI